* AISA THERAPEUTICS *
2005 - IDF Évry (near Paris) www.no-website.net Discovery, Drugs Key words: Vascular endothelium, Inflammation, Nanomolarity, Colitis, Cystic cancer, Nutraceuticals, Anti-stress Mission: to develop new anti-inflammatory molecules for rhumatoid arthritis, obesity, degenerative diseases, aging and metastatic spreading, based on the modulation-inhibition process in vascular permeability Clients: pharmaceutical industry, veterinary industry dalessio@vjf.inserm.fr Age: 3 year(s)
Identity| TYPE/MANAGEMENT/INVESTORS | FINANCES/STATUS | | Personal venture | Managing Dir.: d'Alessio (Patrizia) [founder, born 1952, M.D., ex-Inserm] Sc.Dir.: Fin.Dir.: BusDev: Financers (Hist.): Critt Chimie, Anvar Communication: no available website information and no media release, since company inception | Turnover (M€) : n.a. Total funding (M€) : n.a. Last funding (M€) : n.a. Focus : Inflammation Position : Preclin Company confirm : none |
History | DATE | MILESTONE | TYPE | TIME | | 2007 .10 | Seed financing : undisclosed M€, by 2 business angels | SFIN | [2 years] |
| 2005 .10 | Company founded by Patrizia d'Alesso (Inserm), with Aisa meaning Anti Inflammatory Senescence Actives | ORGF | [0 year] | Actualisation / Updating: 31-Oct-2008 |
|